VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IACH 2021 | Post-transplant cyclophosphamide in chronic GvHD

Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, gives an overview of the latest advances in the treatment of chronic graft-versus-host disease (GvHD). Post-transplant cyclophosphamide has been critical in reducing chronic GvHD following haploidentical and unrelated transplants. Several studies have shown that there was no higher relapse rate amongst patients who received haploidentical transplants with post-transplant cyclophosphamide compared to conventional drugs used in GvHD prophylaxis. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

Disclosures

Arnon Nagler, MD, MSc, is the Co-Chair, Co-Organizer and Co-Founder of the International Academy for Clinical Hematology (IACH),

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter